Verified against court and regulatory records · No upfront fees · Your information is never sold
Qualification
Do You Qualify?
Eligibility checklist
- Used a recalled Philips CPAP, BiPAP, or ventilator device (manufactured approximately 2009–2021)
- Diagnosed with cancer — including nasopharyngeal, lung, kidney, liver, bladder, or throat cancer
- Used the device for at least 6 months prior to cancer diagnosis
- Diagnosis occurred after prolonged device use (cancer latency supports claims even for earlier diagnoses)
- Device was used in a high heat, high humidity, or ozone-cleaned environment (increases exposure)
- Non-cancer injury claimants: documented respiratory, chemical toxicity, or systemic health effects from device use
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
The Wire
Latest in this litigation
- July 2026Search Interest in Philips CPAP Recall Rises SharplyGoogle Trends data recorded a sharp week-over-week rise in searches for terms including "philips cpap recall update," "fda philips cpap recall," and "cpap recall 2026," with several terms marked as "breakout" search activity as of July 24, 2026.
- July 2026Search Interest in Philips CPAP Recall SurgesGoogle Trends data recorded sharp week-over-week increases in searches for terms including "philips cpap recall 2021," "fda philips cpap recall," and "philips cpap recall update," with several related terms reaching "breakout" status. This indicates renewed public attention to the Philips CPAP recall topic, though it does not reflect a new court ruling, settlement, or agency action.
- June 2026Philips CPAP Recall Search Interest Surges Sharply in Late June 2026Google Trends data detected on June 24, 2026 shows a sharp rise in searches related to the Philips CPAP recall. Terms such as "fda cpap recall" rose 850% week-over-week, "philips cpap recall 2021" rose 700%, and "philips cpap recall replacement schedule" reached breakout status. The pattern suggests renewed public attention to the recall and its ongoing impact.
- Full case timeline ↓
Injured? Get a free CPAP Cancer case review.
The carcinogenic mechanism is well-documented: PE-PUR foam absorbs ozone from cleaning devices, accelerating chemical breakdown. Even without ozone cleaning, heat and humidity degrade the foam over time. The resulting VOCs and particulate matter are inhaled nightly by users, often for years. The upper respiratory tract — particularly the nasopharynx — receives the highest direct exposure, explaining the disproportionate prevalence of nasopharyngeal cancer among MDL plaintiffs. Systemic absorption of carcinogenic VOCs through lung tissue explains downstream kidney, liver, and bladder cancers via metabolic processing.
Philips ran a device replacement program, but plaintiffs allege replacements were slow, inadequate, and did not constitute a litigation release. Parallel regulatory action — including a 2023 DOJ/FDA consent decree — required enhanced quality controls but did not resolve civil liability. Market analysts estimate Philips's total exposure at $4 to $6 billion if bellwether verdicts go unfavorably, dwarfing the current $1.1 billion reserve. The Zantac MDL's dismissal on causation grounds is a cautionary precedent Philips hopes to replicate through aggressive Daubert challenges, but the established foam degradation chemistry is significantly stronger evidence than Zantac's epidemiology.
Exposure profiles
Who Is Most at Risk: CPAP Cancer Exposure Profiles
Long-Term CPAP Users (5+ Years of Recalled Device Use)
Moderate riskCommon tasks
- Uses cpap cancer products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Ozone Cleaner Users (SoClean, VirtuCLEAN, or Similar)
High riskCommon tasks
- Uses cpap cancer products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Humidifier Users — Heat and Humidity Accelerated Degradation
High riskCommon tasks
- Uses cpap cancer products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
BiPAP and Ventilator-Dependent Patients — Higher Flow Rates
High riskCommon tasks
- Uses cpap cancer products or devices as described
- Seeks medical evaluation for related symptoms or injuries
- Consults healthcare provider for ongoing care
- Documents exposure history and medical records
Settlement structure
Philips CPAP Lawsuit Settlement Tiers — Estimated Compensation by Injury
Settlement values in MDL 3014 have not been formally announced. The ranges below are based on attorney projections, MDL analogues (3M earplug MDL, Zantac litigation), and the severity of documented injuries. No global settlement matrix has been published as of February 2026.
Non-Cancer Injury (Respiratory/Chemical Toxicity)
ModerateSettlement range
$40,000avg
$20,000 – $75,000
Criteria
- Used a recalled Philips CPAP or BiPAP device
- Experienced documented non-cancer health effects: chronic headaches, sinusitis, respiratory inflammation, chemical irritation, nausea, or worsened COPD/asthma
- Medical records documenting symptoms correlated with device use period
- No cancer diagnosis
Cancer Tier 1 — Early Stage, Favorable Prognosis
SeriousSettlement range
$180,000avg
$100,000 – $300,000
Criteria
- Cancer diagnosis: nasopharyngeal, lung, kidney, liver, bladder, or throat cancer
- Early-stage diagnosis (Stage I or II)
- Successful treatment, good prognosis
- Strong documented device use history (6+ months of recalled device use)
- Medical records linking diagnosis timeline to exposure period
Cancer Tier 2 — Advanced Stage / Significant Treatment
SevereSettlement range
$550,000avg
$300,000 – $900,000
Criteria
- Cancer diagnosis: nasopharyngeal, lung, kidney, liver, bladder, or throat cancer
- Advanced stage (Stage III or IV) or requiring significant treatment (chemotherapy, radiation, surgery)
- Documented multi-year CPAP device use with recalled unit
- Strong causation evidence linking foam exposure to cancer type
- Ongoing treatment or permanent health impairment
Cancer with Wrongful Death or Permanent Severe Disability
CatastrophicSettlement range
$1,750,000avg
$1,000,000 – $3,000,000
Criteria
- Death resulting from cancer causally linked to Philips CPAP foam exposure
- Surviving spouse, dependent child, or estate filing wrongful death claim
- Terminal diagnosis with shortened life expectancy attributable to cancer
- Severe permanent disability resulting from cancer or cancer treatment
- Strongest causation documentation: long-term device use, matched carcinogen-cancer pathway
These are attorney projections based on MDL analogues and are not guaranteed settlement amounts. No global settlement has been announced. Individual case values depend on injury severity, duration of device use, documentation quality, state law, and MDL developments. Consult a qualified attorney for case-specific evaluation.
What claims have reportedly settled for
Reported settlement ranges
Severe Cancer (Nasopharyngeal/Throat)
$500,000$1,500,000
Moderate-Severe Cancer (Lung/Kidney/Liver)
$300,000$900,000
Early-Stage Cancer
$100,000$300,000
Non-Cancer Injury
$20,000$75,000
Wrongful Death (Cancer-Related)
$1,000,000$3,000,000
Ranges reflect publicly reported outcomes in other cases — not a prediction, promise, or guarantee about any individual claim.
Filing deadlines
Philips CPAP Lawsuit Filing Deadlines — MDL 3014 & State Courts
CPAP cancer lawsuits are products liability/personal injury claims with state-specific statutes of limitations. The discovery rule — where the clock starts when you knew or reasonably should have known your cancer was linked to CPAP foam — is critical for cancer latency cases.
Injured? Get a free CPAP Cancer case review.
Internal documents
Internal Documents & Evidence
Australian TGA Precautionary Recall — Philips CPAP Devices (April 2021)
From the record
Impact
FDA Class I Recall Notice — Philips CPAP/BiPAP/Ventilator (June 2021)
From the record
Impact
FDA Laboratory Testing of Recalled Philips Devices — PE-PUR Foam VOC Analysis
From the record
Impact
MDL 3014 Case Management Orders and Bellwether Trial Timeline — W.D. Pa.
From the record
Impact
Philips N.V. 2022 Annual Report — $1.1 Billion Litigation Reserve Disclosure
From the record
Impact
Regulatory actions
FDA Actions and Philips Recall History
The regulatory timeline of the Philips CPAP recall reveals a years-long failure to protect patients. Despite internal complaints about PE-PUR foam degradation dating to 2015, Philips did not initiate a recall until June 2021 — and only after Australian regulators forced its hand months earlier. The FDA classified the recall as Class I (highest severity), issued a formal Warning Letter for inadequate patient notification, and subsequently opened a criminal investigation. Philips has set aside over $1.1 billion in reserves, and the U.S. Department of Justice entered consent decree negotiations — marking one of the most serious regulatory responses to a medical device defect in recent U.S. history.
Voluntary Recall Notification — June 14, 2021
On June 14, 2021, Philips Respironics issued a voluntary recall notification covering approximately 15–16 million CPAP, BiPAP, and mechanical ventilator devices worldwide (approximately 5.5 million U.S. units). The recall cited PE-PUR sound abatement foam degradation causing release of VOCs and particulate matter, with potential health risks including cancer. Philips proposed a repair and replace program but was immediately criticized for the slow rollout and inadequate patient outreach. The recall covered devices manufactured from approximately 2009 through April 2021.
FDA Class I Recall Classification — Most Serious Category
The FDA classified the Philips recall as Class I — the most serious category of medical device recall, reserved for situations where use of or exposure to the product will cause serious adverse health consequences or death. The FDA posted the recall on its MedWatch system and issued public safety communications warning patients not to use recalled devices unless stopping therapy posed greater risk (as with life-sustaining ventilators). The Class I designation significantly elevated the legal liability standard applicable to Philips and supported plaintiffs' negligence per se arguments.
FDA Warning Letter to Philips — Failure to Adequately Notify Patients
In 2022, the FDA issued a formal Warning Letter to Philips Respironics citing multiple violations, including failure to adequately notify device users and healthcare providers of the recall risks, deficiencies in the repair and replacement program, and ongoing manufacturing quality system failures. The Warning Letter found that Philips had not taken sufficient corrective action and that millions of recalled devices remained in use without adequate patient notification. This regulatory finding directly supports plaintiffs' claims that Philips failed its post-recall duty to warn.
$1.1 Billion Reserve Announced for Recall Remediation
Koninklijke Philips N.V. disclosed in its 2022 annual report that it had established a provision of approximately $1.05–1.1 billion USD to cover CPAP recall remediation costs, including the device repair and replacement program and anticipated litigation exposure. The reserve was subsequently maintained and updated in 2023 and 2024 filings. Market analysts estimated Philips' total litigation exposure — including personal injury MDL claims — at $4–6 billion USD if bellwether trials produced adverse verdicts, creating sustained settlement pressure as the MDL advances toward trial in 2026.
Criminal Investigation and Consent Decree Negotiations
The U.S. Department of Justice, working with the FDA, opened a criminal investigation into Philips Respironics relating to its handling of the PE-PUR foam defect and recall. In 2023, Philips entered into a consent decree with the FDA requiring enhanced quality control systems and independent auditing of its manufacturing operations. While the consent decree addressed prospective manufacturing practices, it did not resolve the personal injury MDL or provide any litigation release. The criminal investigation remained active as of early 2026, adding further pressure on Philips to advance settlement negotiations with MDL plaintiffs.
Corporate Impact
Philips Respironics: Corporate Conduct Behind the CPAP Recall
The CPAP recall litigation is not simply a product defect case — it is a case about corporate concealment. Philips Respironics received internal complaints about PE-PUR foam degradation as early as 2015. Rather than investigating and recalling devices, the company allowed millions of patients to continue breathing carcinogenic VOCs every night for six additional years. Even after Australian regulators compelled action in April 2021, Philips delayed U.S. notification by months. When the recall came, replacement devices initially provided to patients were found to contain the same defective foam — extending harm even for those who sought remediation. The pattern of knowing concealment, delayed action, and inadequate remediation forms the foundation of plaintiffs' punitive damages claims in MDL 3014.
Timeline: Philips Respironics / Koninklijke Philips N.V.
Key events on the record
Internal Complaints About Foam Degradation — No Action
Internal Philips documents produced in discovery reveal that the company received complaints and internal reports about PE-PUR foam degradation, discoloration, and odor issues beginning as early as 2015. Rather than conducting a root-cause investigation or initiating a recall, Philips continued manufacturing and selling devices with the same foam formulation. The company maintained its market dominance in the CPAP sector — approximately 40% of the global market — while concealing known foam degradation risks from patients, physicians, and regulators for at least six years.
Australian Recall Precedes US Action by Months
In April 2021, Australia's Therapeutic Goods Administration (TGA) issued a precautionary recall of Philips CPAP and BiPAP devices due to PE-PUR foam safety concerns. Philips had provided information to Australian regulators that it had not yet shared with the FDA or U.S. consumers. The two-month gap between the Australian recall (April 2021) and the U.S. voluntary recall notification (June 2021) is central to plaintiffs' failure-to-warn claims — demonstrating that Philips prioritized regulatory sequencing over patient safety, and that U.S. patients were knowingly exposed for additional months after international action was already underway.
US Voluntary Recall Announced — 15 Million Devices
On June 14, 2021, Philips announced the recall of approximately 15–16 million CPAP, BiPAP, and mechanical ventilator devices globally — one of the largest medical device recalls in U.S. history. The company proposed a repair and replace program but immediately faced criticism for the program's slow rollout: patients waited 12–18+ months for replacement devices, and many were advised by Philips to continue using recalled devices in the interim due to the health risks of untreated sleep apnea. MDL 3014 was consolidated in the Western District of Pennsylvania by October 2021 with Judge Joy Flowers Conti presiding.
Replacement Units Also Found to Contain Defective Foam
In a damaging development for Philips' remediation efforts, FDA testing and independent analysis found that some replacement devices provided to patients as part of the recall repair program contained the same or similar PE-PUR foam formulation — meaning patients who returned their recalled devices and accepted replacements may have continued to face exposure. The FDA issued additional safety communications regarding replacement device concerns. This failure of remediation extended harm to plaintiffs who had taken affirmative steps to protect themselves, and created a distinct category of post-recall injury claims in the MDL.
MDL 3014 Bellwether Selection — $1.1B Reserve — Trial Approaching
By 2023, MDL 3014 had grown to over 80,000 cases, becoming one of the largest active MDLs in the United States. Philips established a litigation reserve of approximately $1.1 billion USD and entered into a DOJ consent decree addressing manufacturing quality systems. Bellwether plaintiff fact sheets, expert discovery, and general causation Daubert proceedings advanced through 2024–2025. As of early 2026, Judge Conti is targeting bellwether trials in 2026 — the outcome of which will set the settlement valuation matrix for all remaining plaintiffs. With over 100,000 cases filed and market analysts estimating $4–6 billion in total exposure, settlement pressure on Philips is intensifying.
From the docket
Litigation Timeline
- 2015-01-01
Philips Receives Internal Foam Degradation Complaints
Internal Philips Respironics documents indicate the company began receiving complaints about PE-PUR foam degradation in CPAP devices as early as 2015. Despite these early warning signs, Philips took no corrective action for approximately six years — a central allegation in the MDL litigation establishing corporate negligence.
- 2021-06-14
Philips Issues Voluntary Recall — 15 Million Devices Affected
Philips Respironics issued a voluntary recall of approximately 15 to 16 million CPAP, BiPAP, and mechanical ventilator devices worldwide (approximately 5.5 million U.S. units). The recall cited PE-PUR foam degradation as a potential health risk, including release of VOCs and particulate matter into the breathing pathway. The affected model range spans 2009–2021, including the DreamStation, System One, REMstar, and other product lines.
- 2021-07-01
FDA Elevates to Class I Recall — Highest Severity
The FDA classified the Philips CPAP recall as a Class I recall — its most serious category, indicating a reasonable probability that use of the recalled devices will cause serious adverse health consequences or death. FDA testing subsequently identified over 200 chemical compounds in degraded PE-PUR foam, including known and suspected human carcinogens such as toluene diisocyanate and dimethylformamide.
- 2021-10-01
MDL 3014 Formed in Western District of Pennsylvania
The Judicial Panel on Multidistrict Litigation (JPML) consolidated Philips CPAP personal injury cases into MDL 3014 in the U.S. District Court for the Western District of Pennsylvania in Pittsburgh. Chief Judge Joy Flowers Conti was assigned to preside over the litigation, which is headquartered in Philips Respironics's home district. MDL 3014 docket: 2:21-mc-01230-JFC.
- 2024-01-01
Philips Reserves $1.1 Billion — Daubert Battles Intensify
Philips N.V. disclosed approximately $1.05–1.1 billion USD in litigation reserves in its 2024 annual report. The MDL entered a critical phase of general causation expert discovery and Daubert motion practice, with Philips aggressively challenging plaintiffs' expert testimony on the causal link between foam VOC exposure and specific cancers. Bellwether trial pools were identified for a 2026 trial schedule.
- 2026-01-01
Bellwether Trials Targeting 2026 — Settlement Pressure Building
As of early 2026, MDL 3014 has over 100,000 personal injury cases filed and is advancing toward bellwether trials on a 2026 schedule. No global settlement has been announced, but market analysts estimate total Philips liability exposure at $4–6 billion. Philips's $1.1 billion reserve is widely viewed as insufficient if bellwether verdicts go unfavorably, creating significant pressure for a global resolution similar to the 3M earplug MDL's $6 billion settlement.
- June 2026
Philips CPAP Recall Search Interest Surges Sharply in Late June 2026regulatory
Google Trends data detected on June 24, 2026 shows a sharp rise in searches related to the Philips CPAP recall. Terms such as "fda cpap recall" rose 850% week-over-week, "philips cpap recall 2021" rose 700%, and "philips cpap recall replacement schedule" reached breakout status. The pattern suggests renewed public attention to the recall and its ongoing impact.
- June 2026
Search Interest in Philips CPAP Recall Spikes Sharplyregulatory
Google Trends data detected on June 24, 2026 shows a dramatic surge in CPAP recall-related searches. Terms like 'fda cpap recall' rose 850% week-over-week and 'philips cpap recall 2021' rose 700%, while several other related queries hit breakout status. The pattern suggests a renewed wave of public attention to the ongoing Philips CPAP recall issue.
- July 2026
Search Interest in Philips CPAP Recall Rises Sharplyregulatory
Google Trends data recorded a sharp week-over-week rise in searches for terms including "philips cpap recall update," "fda philips cpap recall," and "cpap recall 2026," with several terms marked as "breakout" search activity as of July 24, 2026.
- July 2026
Search Interest in Philips CPAP Recall Surgesregulatory
Google Trends data recorded sharp week-over-week increases in searches for terms including "philips cpap recall 2021," "fda philips cpap recall," and "philips cpap recall update," with several related terms reaching "breakout" status. This indicates renewed public attention to the Philips CPAP recall topic, though it does not reflect a new court ruling, settlement, or agency action.
Injured? Get a free CPAP Cancer case review.
Medical condition
Kidney and Liver Cancer (CPAP Chemical Exposure)
Medical definition
Renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) have been reported in Philips CPAP MDL plaintiffs. The carcinogenic mechanism involves systemic absorption of VOCs released by degraded PE-PUR foam through the respiratory mucosa and pulmonary circulation, with subsequent metabolic processing in the kidneys and liver. Carcinogens including dimethylacetamide (DMAC) and diethylene glycol are excreted or metabolized by these organs, causing direct nephrotoxic and hepatotoxic carcinogenic effects.
Symptoms
Blood in urine (hematuria) — kidney
CommonFlank pain or back pain — kidney
CommonAbdominal mass — kidney
SeriousRight upper quadrant abdominal pain — liver
CommonJaundice (yellowing of skin/eyes) — liver
SeriousUnexplained weight loss (both)
SeriousFatigue and weakness (both)
CommonRisk Factors
- Systemic absorption of nephrotoxic and hepatotoxic VOCs from foam degradation
- Prolonged duration of recalled Philips device use
- Pre-existing liver conditions (hepatitis B/C — synergistic with HCC)
- Metabolic processing of inhaled carcinogens through renal and hepatic pathways
- High cumulative chemical exposure (ozone cleaning, high-humidity use environment)
Treatment Options
Medical condition
Lung Cancer (CPAP Foam Exposure)
Medical definition
Lung cancer in Philips CPAP litigation refers to primary bronchogenic carcinoma — most commonly adenocarcinoma or squamous cell carcinoma — arising in users of recalled Philips devices who inhaled PE-PUR foam degradation byproducts over prolonged periods. The carcinogens released, including TDI (a known respiratory carcinogen), dimethylformamide, and particulate foam fragments, cause direct pulmonary tissue damage and mutagenesis.
Symptoms
Persistent cough (new or worsening)
CommonHemoptysis (coughing blood)
SeriousShortness of breath
CommonChest pain
CommonUnexplained weight loss
SeriousHoarseness
CommonRecurrent respiratory infections
CommonRisk Factors
- Nightly inhalation of foam particulates and VOCs during sleep
- Ozone cleaner use (dramatically increases foam degradation rate)
- Concurrent tobacco use (synergistic carcinogenic risk)
- Underlying respiratory conditions (COPD, asthma — increases mucosal absorption)
- Extended duration of recalled device use
- High-humidity sleep environments (accelerates foam off-gassing)
Treatment Options
Medical condition
Nasopharyngeal Cancer
Medical definition
Nasopharyngeal carcinoma (NPC) is a malignant tumor arising from the epithelial cells of the nasopharynx — the upper part of the throat behind the nose. In the context of Philips CPAP litigation, NPC is the most prevalent cancer type among MDL plaintiffs, attributable to direct inhalation of PE-PUR foam degradation byproducts including toluene diisocyanate (TDI) and volatile organic compounds into the nasopharyngeal mucosa during device use.
Symptoms
Nasal congestion or blockage
CommonNosebleeds (epistaxis)
CommonNeck lump (swollen lymph node)
CommonHearing loss or ear fullness (Eustachian tube involvement)
CommonHeadache
CommonDouble vision or facial numbness (advanced)
SevereDifficulty swallowing or speaking (advanced)
SevereRisk Factors
- Prolonged inhalation of carcinogenic VOCs from PE-PUR foam degradation
- Use of ozone-based CPAP cleaners (accelerates foam breakdown)
- High heat/humidity device environment
- Duration of recalled Philips CPAP/BiPAP device use (longer = greater exposure)
- Pre-existing Epstein-Barr virus infection (synergistic risk with chemical exposure)
Treatment Options
Medical condition
Non-Cancer Chemical Toxicity and Respiratory Injury
Medical definition
Many Philips CPAP recall plaintiffs did not develop cancer but experienced significant non-malignant health effects from chronic inhalation of PE-PUR foam degradation byproducts. These include mucosal irritation, sinusitis, chemical toxicity syndromes, worsened obstructive lung disease, and systemic inflammatory responses. While lower in settlement value than cancer claims, documented non-cancer injuries from recalled device use are viable personal injury claims.
Symptoms
Chronic headaches and migraines
CommonEye, nose, and throat irritation
CommonChronic sinusitis or rhinitis
CommonNausea and dizziness
CommonWorsening of existing COPD or asthma
SeriousChemical sensitivity (multiple chemical sensitivity syndrome)
ModerateRespiratory inflammation and reactive airway disease
CommonRisk Factors
- Any use of recalled Philips CPAP or BiPAP device
- Ozone-based device cleaning (highest exposure risk)
- Pre-existing respiratory conditions (amplifies injury severity)
- High-humidity bedroom environment
- Longer duration of device use
Treatment Options
Dive deeper
In-Depth Guides
Deadlines & venues
Deadlines & Venues by State
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Keep reading
Explore This Litigation
Stay informed
Get free updates on the CPAP Cancer litigation as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Sources & References
- —
- —
- —
- —
- —
- —
- —